Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It se… Read more
Neuraxis, Inc. (NRXS) - Net Assets
Latest net assets as of September 2025: $2.28 Million USD
Based on the latest financial reports, Neuraxis, Inc. (NRXS) has net assets worth $2.28 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.78 Million) and total liabilities ($3.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.28 Million |
| % of Total Assets | 39.56% |
| Annual Growth Rate | 5.91% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Neuraxis, Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Neuraxis, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neuraxis, Inc. (2020–2024)
The table below shows the annual net assets of Neuraxis, Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.07 Million | +247.36% |
| 2023-12-31 | $-1.40 Million | +74.82% |
| 2022-12-31 | $-5.57 Million | -575.05% |
| 2021-12-31 | $-825.66K | -150.23% |
| 2020-12-31 | $1.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neuraxis, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3067627700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.99K | 0.34% |
| Other Components | $58.86 Million | 2846.59% |
| Total Equity | $2.07 Million | 100.00% |
Neuraxis, Inc. Competitors by Market Cap
The table below lists competitors of Neuraxis, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Acorn Energy, Inc. Common Stock
OTCQB:ACFN
|
$23.47 Million |
|
Heubach Colorants India Limited
NSE:HEUBACHIND
|
$23.49 Million |
|
Numulae Gestion de Servicios SOCIMI SA
MC:YNUM
|
$23.49 Million |
|
LSL Pharma Group Inc.
V:LSL
|
$23.50 Million |
|
Camus Engineering & Construction Inc
KO:013700
|
$23.47 Million |
|
MOTORK LTD. EO -01
F:5FS
|
$23.47 Million |
|
Hep Tech Co Ltd
TWO:3609
|
$23.45 Million |
|
Company K Partners Limited
KQ:307930
|
$23.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neuraxis, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,403,241 to 2,067,748, a change of 3,470,989.
- Net loss of 8,241,501 reduced equity.
- New share issuances of 5,253,663 increased equity.
- Other factors increased equity by 6,458,827.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.24 Million | -398.57% |
| Share Issuances | $5.25 Million | +254.08% |
| Other Changes | $6.46 Million | +312.36% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Neuraxis, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 23.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 22.89x to 23.39x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.31 | $6.99 | x |
| 2021-12-31 | $-0.15 | $6.99 | x |
| 2022-12-31 | $-0.66 | $6.99 | x |
| 2023-12-31 | $-0.22 | $6.99 | x |
| 2024-12-31 | $0.30 | $6.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neuraxis, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -398.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -306.84%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 2.30x
- Recent ROE (-398.57%) is below the historical average (-125.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -226.69% | -193.04% | 0.69x | 1.70x | $-3.89 Million |
| 2021 | 0.00% | -111.27% | 3.58x | 0.00x | $-2.95 Million |
| 2022 | 0.00% | -178.05% | 1.81x | 0.00x | $-4.22 Million |
| 2023 | 0.00% | -594.57% | 4.83x | 0.00x | $-14.49 Million |
| 2024 | -398.57% | -306.84% | 0.56x | 2.30x | $-8.45 Million |
Industry Comparison
This section compares Neuraxis, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neuraxis, Inc. (NRXS) | $2.28 Million | -226.69% | 1.53x | $23.47 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |